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Abstract 
Tubulo-interstitial fibrosis has been recognized as the hallmark of progression of chronic kidney disease, but, despite 
intensive research studies, there are currently no biomarkers or effective treatments for this condition. In this context, 
a promising candidate could be heparanase-1 (HPSE), an endoglycosidase that cleaves heparan sulfate chains and 
thus takes part in extracellular matrix remodeling. As largely described, it has a central role in the pathogenesis of 
cancer and inflammation, and it participates in the complex biological machinery involved in the onset of different 
renal proteinuric diseases (e.g., diabetic nephropathy, glomerulonephritis). Additionally, HPSE may significantly influ-
ence the progression of chronic kidney damage trough its major role in the biological pathway of renal fibrogenesis. 
Here, we briefly summarize data supporting the role of HPSE in renal damage, focusing on recent evidences that 
demonstrate the capability of this enzyme to modulate the signaling of pro-fibrotic factors such as FGF-2 and TGF-β 
and consequently to control the epithelial-mesenchymal transition in renal tubular cells. We also emphasize the need 
of the research community to undertake studies and clinical trials to assess the potential clinical employment of this 
enzyme as diagnostic and prognostic tool and/or its role as therapeutic target for new pharmacological interventions.
© 2015 Masola et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Although improvements in drug therapies over the years 
have significantly slowed the progression of chronic kid-
ney disease (CKD) to end-stage renal disease (ESRD), 
we still remain far from being able to prevent a sizable 
proportion of patients from ultimately need for dialysis 
or transplantation [1]. Therefore, because of the large 
worldwide diffusion of this clinical condition, this repre-
sents an important issue in medicine.
The US Renal Data System’s 2013 Annual Data Report 
indicates that more than 10% of the US adult population 
suffers from CKD [2]. In Italy, 13% of people over age 40 
have CKD [3]. CKD and ESRD have a significant impact 
on health care costs. In the US, the cost of CKD patients 
over age 65 exceeds $45 billion [2].
Clinical-pathological studies have clearly shown that 
tubulo-interstitial fibrosis (TIF) is pivotally involved in 
the onset and progression of chronic renal damage and it 
could be considered a reliable prognostic marker of CKD, 
regardless of the etiology and the origin of the primary 
disease [4].
However, at the moment, main causes of renal fibrosis 
in developed countries are type 2 diabetes mellitus and 
ischemic/hypertensive nephropathy [5].
Additionally, despite numerous research efforts [6], no 
effective treatments or biomarkers are currently avail-
able for the progression of renal fibrosis. One interesting 
molecule that could be employed both as a biomarker 
and a pharmacological target is heparanase-1 (HPSE) 
an enzyme involved in the pathogenesis of several 
nephropathies [7] that cleaves heparan sulfate (HS) and 
thus takes part in the remodeling of the extracellular 
matrix (ECM) [8], a complex structure that acts as a scaf-
fold for cell attachment, proliferation and differentiation, 
and modulates cell signaling [9].
The renal ECM consists of specific, specialized struc-
tures as the tubular and peritubular capillary basement 
membranes, and the glomerular basement membrane, 
but it also exists as an “amorphous” mesangial and inter-
stitial matrix [10]. ECM remodeling by HPSE thus lies at 
the hub of networks integrating different mechanisms in 
renal fibrosis.
Mechanisms of renal fibrosis
During renal fibrosis, the accumulation of abnormal 
ECM alters the three-dimensional structure of all the 
renal structures (glomeruli, tubules, interstitium and 
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vasculature) and it induces a failure of the physiologi-
cal mechanisms of response to acute insult and/or tissue 
regeneration. Several factors could be involved in this 
deregulated machinery (e.g., cytokines, ROS, or inflam-
matory cells) [11].
The main macroscopic features of renal fibrosis (glo-
merulosclerosis, TIF, inflammatory infiltration, and loss 
of renal parenchyma, characterized by tubular atrophy, 
capillary loss, and podocyte depletion) are caused by sev-
eral biological events including mesangial and fibroblast 
activation, monocyte/macrophage and T cell infiltration, 
and cell apoptosis. The accumulation of connective tissue 
and infiltration of inflammatory cells and myofibroblasts 
into the renal parenchyma result in irreversible organ 
damage [11]. Activated myofibroblasts in the tubular 
compartment and mesangial cells in the glomeruli are 
key producers of ECM (collagen IV, laminin, fibronec-
tin) and major responsible for TIF and glomerulosclero-
sis, respectively. Both these cell lines have also properties 
similar to contractile smooth muscle, since they express 
α-smooth muscle actin (α-SMA) [11]. In the kidney, 
myofibroblasts originate from several sources: (1) inter-
stitial renal fibroblasts; (2) interstitial perivascular cells 
called pericytes; (3) fibrocytes; (4) tubular epithelial cells; 
and (5) endothelial cells [6, 12].
Tubular epithelial-mesenchymal transdifferentiation 
(EMT) into myofibroblasts, is a process first identified 
in mice and, more recently, in humans, representing an 
important source of these cells in kidney, contributes to 
the onset of TIF (Figure 1: top) and to the progression of 
CKD [13]. During this process, which ultimately deter-
mine renal fibrosis, the interstitial microenvironment 
is enriched with cytokines and chemokines released 
by the tubular epithelial cells in response to proteinu-
ria, high glucose concentrations, advanced glycosyla-
tion end products (AGE), reactive oxygen species and 
hypoxia. Macrophages and lymphocytes attracted by 
the chemokines release additional factors, such as trans-
forming growth factor-β (TGF-β), epidermal growth fac-
tor (EGF), and fibroblast growth factor-2 (FGF-2) [14]. 
All these stimuli contribute to EMT of tubular epithelial 
cells.
In particular, TGF-β seems to be primarily involved 
in the onset and progression of renal fibrosis in dia-
betic nephropathy (DN) [15]. In this pathological condi-
tion, the excess AGE and albumin filtering through the 
Figure 1 EMT process and signaling pathway. During EMT, tubular epithelial cells turn off the expression of adhesion molecules (E-cadherin, 
claudins and cytokeratins), and upregulate mesenchymal markers such as vimentin (VIM), fibronectin (FN), α-SMA, and fibroblast-specific protein-1 
(FSP1). Subsequently, they undergo a reorganization of the cytoskeleton and a change in their morphology. The transition process from epithelial  
to mesenchymal phenotype is gradual and it involves intermediate morphological changes [14]. Degradation of the tubular basement membrane 
and migration of the transformed epithelial cells into the interstitium complete the EMT. The table at the bottom summarizes the main EMT  
triggers and the signaling pathways that they activate.
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glomeruli also promotes EMT by directly stimulating the 
tubular cells to produce TGF-β [16].
Many other factors have been identified as EMT trig-
gers and, together with TGF-β, they activate multiple 
and, in some cases, “redundant” signaling pathways such 
as SMAD, MAPK, PI3-K/Akt, RhoA [17–19] (Figure  1: 
bottom).
Heparanase
HPSE is an endo-β (1-4)-d-glucuronidase that cleaves 
the β-(1,4)-glycoside bonds on the HS of HS-proteo-
glycans (HSPGs) leading to the production of HS frag-
ments approximately 5–10  kDa [19]. The active form 
of this enzyme is a heterodimer consisting of a 50  kDa 
subunit associated non-covalently with an 8 kDa subunit 
[20]. The HPSE gene (50  kb) is on chromosome 4q21.3 
and comprises 14 exons and 13 introns coding a precur-
sor (pre-HPSE) that is post-translationally converted 
first into pro-HPSE and then into mature HPSE [19]. The 
inactive pro-HPSE (65  kDa) is transferred to the Golgi 
apparatus, where it is packaged in vesicles to be secreted 
from the cell. Once in the extracellular space, pro-HPSE 
interacts with syndecans and the pro-HPSE/syndecan 
complex is endocytosed [20]. Pro-HPSE can also be 
internalized by low-density lipoprotein receptor-related 
proteins and mannose 6-phosphate receptors [21]. Once 
inside the lysosomes, cathepsin-l cleaves the linker pep-
tide from the pro-HPSE, yielding an heterodimer com-
posed of 8- and 50-kDa subunits, thus activating HPSE 
(Figure 2).
Given its ability to degrade the HS chains, the main 
physiological function of heparanase is to regulate HS 
turnover and then participate in the remodeling of the 
ECM and basement membranes [20]. Nevertheless, 
HPSE triggers a number of signaling pathways by: (1) 
digesting HS chains and causing the release of growth 
factors and cytokines bound to HS, thereby regulating 
their free levels in the pericellular microenvironment; (2) 
interacting via its C-terminal domain [22], with several 
transmembrane heparanase-binding proteins (HBP) and 
activating kinases such as Src, Akt, and p38 MAPK; (3) 
modulating the activity of the FGF-2 and TGF-β signal-
ing cascades [23, 24] and (4) converting the soluble HS 
fragments of SDC1 from inhibitors into potent activators 
of FGF-2 signaling [25].
In non-pathological conditions, HPSE is produced by 
placental trophoblasts, blood-borne cells and keratino-
cytes [19]. Although the participation of HPSE in a num-
ber of physiological processes (e.g., embryo implantation 
and development, hair growth, and inflammatory pro-
cesses) [26], researchers nowadays are mainly focusing 
on its involvement in pathological conditions including 
tumor progression and renal diseases.
Heparanase and renal fibrosis
Several studies of proteinuric renal diseases performed 
in animal models (puromycin amino nucleoside-induced 
nephrosis, streptozotocin-induced diabetic nephropa-
thy and adriamycin nephropathy) and humans (diabetic 
nephropathy, membranous glomerulonephritis, IgA 
Figure 2 Graphical representation of HPSE maturation. The pro-enzyme is secreted from the Golgi complex. In the extracellular space, it interacts 
with syndecans or other receptors that mediate its endocytosis. The pro-enzyme is activated into lysosomes by cathepsin-l. Then active HPSE is 
secreted into the extracellular milieu.
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nephropathy, minimal change disease and dense deposit 
disease) have found a significant HPSE over-expression 
in the kidney tissue [27–29].
Additionally, since HPSE expression correlates 
inversely with HS content in the glomerular basement 
membrane, it has been suggested that the degradation 
of the glomerular HS by HPSE plays a role in the devel-
opment of proteinuria [28, 30] particularly in diabetic 
nephropathy [7, 27, 29]. HPSE, constitutively expressed 
in human tubular epithelial cells, has also a physiological 
role in maintaining cellular and ECM homeostasis [31].
Changes in aforementioned balance, at least, partially 
determined by an abnormal HPSE regulation/activity, 
induce pathogenic mechanisms responsible for the onset 
of chronic kidney damage. In fact, in a model of type 1 
diabetes induced by streptozotocin, HPSE-ko mice fail 
to develop chronic nephropathy [32] because protected 
against the onset of proteinuria and TIF [32].
HPSE expression is upregulated by transcription factors 
such as Sp1, GA-binding protein (GABP), ETS1, ETS2, 
early growth response-1 (EGR1), and downregulated by 
the transcription factor p53, and by DNA methylation. 
HPSE is also modulated by a variety of endogenous mol-
ecules: elastase, tissue plasminogen activator, thrombin, 
high glucose levels, angiotensin II and aldosterone, free 
radicals, pro-inflammatory cytokines, fatty acids, tissue 
necrosis factor-α (TNF-α), vascular endothelial growth 
factor (VEGF), and estrogens [7, 19].
Moreover, several pro-fibrotic factors such as albu-
minuria, high glucose concentrations, advanced gly-
cosylation end products (AGE), TGF-β and FGF-2 can 
upregulate HPSE expression [23, 31] (Figure 3A) by acti-
vating PI3K/AKT [23, 31], a signaling pathway involved 
in the EMT of renal tubular cells [33]. The overexpres-
sion of HPSE can trigger HS degradation and modulate 
the expression of syndecan-1 (SDC1), the most abundant 
HSPGs on epithelial cells (Figure 3B). In this condition, 
the abnormal remodeling of HS and SDC1 can increase 
the availability of growth factors (e.g., FGF-2 and TGF-β 
leading to TIF).
Our in vitro data indicated that renal tubular cells lack-
ing HPSE did not undergo EMT induced by FGF-2 and 
TGF-β [23]. This was mainly due to an over-expression of 
SDC1 on HPSE-silenced cells surface that has low affin-
ity for FGF-2. In tubular cells lacking HPSE, the second-
ary impairment of PI3K/AKT pathway also jeopardizes 
the EMT induced by FGF-2. In addition, since FGF-2 is 
unable to increase the expression and activity of HPSE in 
such HPSE-deficient cells, the conversion of the soluble 
HS fragments of SDC1 from inhibitors into potent acti-
vators of FGF-2 signaling is prevented [23] (Figure  3C). 
Overall, HPSE is needed for FGF-2 to induce EMT in 
tubular cells, and to sustain FGF-2 signaling.
HPSE regulates TGF-β-related EMT [34], as well as its 
production. In fact, diabetic HPSE-ko mice, contrarily to 
the wild-type, did not show TGF-β increment in renal tis-
sue and did not develop proteinuria, mesangial matrix 
expansion or TIF [32].
As demonstrated by our group, this effect could be par-
tially explained by the fact that pro-fibrotic factors (albu-
min, AGE and FGF-2) need HPSE in order to upregulate 
TGF-β expression in renal tubular cells. Additionally, a 
lack of HPSE delays the onset of EMT induced by TGF-β 
and hampers the autocrine loop induced by TGF-β [24].
Another way in which HPSE may contribute to the 
progression of renal damage lies in its effect to regulate 
inflammation [35]. This effect has been reported in other 
chronic diseases [36, 37].
In a recent paper, Gil et al. reported that HPSE-ko mice 
showed no significant infiltration of F4/80-positive mac-
rophages in the renal parenchyma after the induction 
of type 1 diabetes, unlike wild-type animals [32]. Gold-
berg et al. [38] have also recently shown that HPSE fuels 
chronic inflammation in diabetic nephropathy: inactive 
HPSE produced by glomeruli and activated by cathepsin-
l released by tubular cells sustains a persistent activation 
of kidney-damaging macrophages, thus creating chronic 
inflammatory conditions and fostering macrophage-
mediated renal injury (Figure 4).
Overall, the ability of HPSE to regulate multiple mech-
anisms (glomerular permselectivity, tubular cell EMT, 
inflammation) makes it a central player in the fibrogenic 
process of diabetic nephropathy and, since similar mech-
anisms occur in other chronic kidney diseases (including 
chronic allograft dysfunction), it could be an effective 
therapeutic target.
Figure 3 HPSE regulation and control of EMT induced by FGF-2. In 
the epithelial renal tubular cells (A), pro-fibrotic factors (albuminuria, 
AGE, and FGF-2) upregulate HPSE expression by activating PI3K/
AKT; B HPSE overexpression triggers HS degradation and modulates 
syndecan-1 (SDC1) expression; C soluble HS fragments of SDC1 are 
potent FGF-2 signaling activators and thus facilitate tubular cell EMT.
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Heparanase as a biomarker
Heparanase has been detected in the plasma of neoplas-
tic patients and its expression has been correlated with a 
better survival rate [39–41].
Increased urine and plasma levels of HPSE have been, 
also, reported in patients affected by a number of renal 
diseases (mainly diabetic nephropathy). In diabetes, 
HPSE levels correlated with blood glucose levels [42, 
43] and, because involved in the atherosclerotic plaque 
development, it has been proposed as biomarker to 
early identify patients with DN at high risk to develop 
cardiovascular complications [44]. In kidney transplant 
recipients, plasma HPSE levels were associated with pro-
teinuria and renal allograft function impairment [45].
Furthermore, our unpublished data, obtained by ana-
lyzing several chronic kidney diseases, suggest that HPSE 
levels are inversely associated with the degree of renal 
function impairment.
Cohen-Mazor et  al. [46] reported that plasma lev-
els of HPSE were higher in hemodialysis patients com-
pared to healthy subjects probably due to degranulation 
of primed circulating PBMC during the dialysis session. 
This was later confirmed by our findings showing that 
HPSE expression in peripheral blood mononuclear cells 
(PBMC) and plasma were significantly up-regulated in 
both peritoneal- and hemo-dialysis treated patients [47]. 
The significant correlation between HPSE plasma activity 
and C-reactive protein levels also demonstrated a close 
involvement of the microinflammation in the proteogly-
can metabolism deregulation in uremic patients [47].
However, future investigations are necessary to eluci-
date whether urinary or plasma HPSE levels could serve 
as biomarkers of the onset and progression of fibrosis.
Heparanase as pharmacological target
In the last years, a number of HPSE inhibitors have 
been developed and some of them have entered clini-
cal trials for cancer [48–50]. They include heparan sul-
fate mimetics, heparin-derived compounds, or other 
oligosaccharides that compete with the heparan sulfate 
chain for binding to heparanase [49]. Glycosaminogly-
cans such as sulodexide are effective HPSE inhibitors 
[51] and consequently have potential as drugs for the 
treatment of CKD and preventing progression to renal 
failure [52].
Important evidence of the utility of anti-HPSE thera-
pies to control the progression of renal fibrosis comes 
from both in vitro and in vivo studies. In tubular cells, 
HPSE inhibition prevents the HS degradation induced by 
pro-fibrotic factors [31], EMT induced by FGF-2 [23, 51], 
and TGF-β upregulation after treatment with pro-fibrotic 
factors [24]. In animal models, a beneficial effect on the 
onset and development of diabetic nephropathy, and on 
the renal overexpression of TGF-β has been obtained 
with heparin-derived drugs [53], and sulodexide [54]. 
This issue was specifically investigated in mouse models 
of DN using the specific heparanase inhibitor SST0001, 
which markedly reduced the extent of albuminuria and 
renal damage [32].
Moreover, targeting HPSE in CKD could be useful for 
reducing the risk of cardiovascular complications [55]. 
Sulodexide seems to have some interesting favorable 
effects in the prevention and treatment of the complica-
tions of atherosclerosis, possibly supporting its role as 
HPSE inhibitor [56, 57].
Conclusion
Several studies revealed that HPSE plays a pivotal role in 
the pathogenesis of a great number of renal diseases (e.g., 
diabetic nephropathy, chronic allograft nephropathy) and 
in the progression of chronic renal damage.
However, at the moment, we are far from an employ-
ment of HPSE measurement in the “day by day” clinical 
practice and it is unquestionable that additional stud-
ies and clinical trials should be undertaken to assess 
its potential employment as diagnostic and prognostic 
tool and/or therapeutic target for new pharmacological 
interventions.
Figure 4 Involvement of HPSE in renal fibrosis. Several factors (high 
glucose concentrations, ROS, AGE) can increase HPSE production in 
both glomerular and tubular cells. The same factors induce cathep-
sin-l production by renal tubular cells, and this activates HPSE. Then 
the active HPSE can sustain inflammation by activating macrophages 
recruited from the circulation. During stress conditions both tubular 
and inflammatory cells release FGF-2 and TGF-β that, thanks to the 
higher amounts of HPSE, may activate the intracellular machinery 
leading to EMT.
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